DongBang Medical

240550 · KOSDAQ · ₩240550 · 동방메디컬

₩5,060▼ ₩240 (4.53%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩13,558

vs the current price (₩5,060)

Enterprise value
₩284B
Equity value
₩284B
WACC
7.2%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 168% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩5,060, the model needs an operating margin of 7.0% every year (it uses 15.6%).
  • Or revenue growth −27.4 points a year higher than assumed in each of the 5 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩8,692
+71.8%
Base
₩13,558
+167.9%
Bull
₩21,787
+330.6%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (15.6%).

Revenue growth

  • 8%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.

  • 6.8%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.

  • 5.5%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.

  • 4.3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (8% a year, annual reports), fading to 3% by year 5.

Business

  • 15.6%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so a typical level.

  • 4%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: not in the statements, so a typical level.

  • 34.6%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 89 weeks of weekly returns against KOSPI (official index); raw beta 0.08, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩125B
Net debt (borrowings and leases − cash and deposits)
₩4.8B
+ Stakes and investments
₩7.8B
Associates, long-term financial assets and deposits (book value)
− Minority interests
₩2.9B
Shares
20,933,940
Share price
₩5,060
Market cap
₩106B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩105B₩114B₩135B₩144B₩152B₩159B₩164B
Growth—8.0%8.0%6.8%5.5%4.3%3.0%
EBIT₩15B₩17B₩21B₩23B₩24B₩25B₩26B
EBIT margin14.3%15.0%15.6%15.6%15.6%15.6%15.6%
After-tax EBIT₩11B₩12B₩15B₩16B₩17B₩18B₩18B
+ Depreciation——₩4.1B₩4.3B₩4.6B₩4.8B₩4.9B
− Capital spending——₩5.4B₩5.8B₩6.1B₩6.4B₩6.5B
− Working capital—₩6.7B₩3.5B₩3.2B₩2.7B₩2.3B₩1.6B
Free cash flow——₩10B₩12B₩13B₩14B₩15B
Discount factor——0.9330.8700.8110.7560.705
Present value——₩9.8B₩10B₩11B₩11B₩11B

Terminal value ₩329B, worth ₩232B today: 82% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.2%₩14,433₩15,538₩16,902₩18,628₩20,884
6.7%₩13,109₩13,989₩15,052₩16,365₩18,026
7.2%₩11,999₩12,711₩13,558₩14,581₩15,844
7.7%₩11,055₩11,640₩12,325₩13,139₩14,123
8.2%₩10,243₩10,729₩11,291₩11,950₩12,732

Now (TTM)

Market cap
₩106B
Enterprise value
₩111B
P/E
6.6×
P/B
0.8×
P/S
0.8×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

2025
Price₩7,810
Market cap₩163B
P/E14.0×
P/B1.3×
P/S1.4×
EV/EBITDA—
Dividend yield0.0%

Loading data for this company — check back soon

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
DongBang Medical6.6×0.8×0.8×—0.0%
TSE27.5×6.1×5.1×—0.2%
Kctech22.1×3.4×4.1×17.1×0.5%
Classys12.7×3.2×4.7×9.9×3.7%
Park Systems69.0×4.7×8.2×—0.2%
DI42.2×5.8×2.6×—0.6%
Curiox Biosystems—21.3×182.0×—0.0%
Similar companies (median)27.5×5.3×4.9×13.5×0.3%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: DongBang Medical / 동방메디컬 / 240550 / KRX:240550

Source: KRX statistical information